OncLive SOSS

Authors

Pier Luigi Zinzani, MD, PhD, University of Bologna Institute of Hematology

Pierfranco Conte, MD

Latest:

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Pierluigi Porcu, MD,

Latest:

Dr. Porcu on the Need for Diverse Representation in Clinical Trials

Pierluigi Porcu, MD, discusses the need for diverse representation in clinical trials.

Pierre Gholam, MD, UH Westlake Health Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Pieter Sonneveld, MD, PhD

Latest:

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Pieternella J. Lugtenburg, MD, PhD

Latest:

Dr. Lugtenburg on Maintenance Rituximab in DLBCL

Pieternella J. Lugtenburg, MD, PhD, an internist and hematologist at Erasmus Medical Center in Rottenham, Netherlands, discusses the use of rituximab as maintenance therapy in patients with diffuse large B-cell lymphoma.

Pinkal Desai, MD, MPH

Polly Mazanec, PhD, ACNP, AOCN, FPCNÂ

Latest:

Managing Chemotherapy-Induced Peripheral Neuropathy

Chemotherapy-induced peripheral neuropathy is a common side effect in patients with cancer and nurses are essential to helping patients to manage this condition.

Pooja Murthy, MD

Latest:

Integrating PARP Inhibitors Into the Treatment of Women

After years in development, several PARP inhibitors have achieved indications in ovarian cancer treatment, while others continue in development and expanding indications.

Prachi Patel-Predd

Latest:

News Reports: April 2007

News reports featured in this issue: 1) Breast Cancer Spotlight 2) Expert Cancer Centers Cost-Effective for Managing Ovarian Cancer 3) New Breathalyzer

Prajnan Das, MD, MPH

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Pramod K. Mistry, MD, PhD

Latest:

Dr. Mistry on Gaucher Disease Entering a New Era

Dr. Pramod Mistry from Yale University School of Medicine on Gaucher Disease Entering a New Era

Prapti Patel, MD

Latest:

Dr. Patel on the Clinical Implications of Luspatercept Approval in MDS

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

Prasad S. Adusumilli, MD

Latest:

Dr. Adusumilli on the Rationale for Mesothelin-Targeted CAR T-Cell Therapy

Prasad S. Adusumilli, MD, surgeon, deputy chief of Thoracic Service, co-director of the Mesothelioma Program, head of Solid Tumors Cell Therapy, Cellular Therapeutics Center, at Memorial Sloan Kettering Cancer Center, discusses the rationale for an autologous mesothelin-targeted CAR T-cell therapy in advanced solid tumors.

Prasad S. Adusumilli, MD, FACS

Latest:

Dr. Adusumilli on the Development of CAR T Cells in Solid Tumors

Prasad S. Adusumilli, MD, FACS, discusses the current role of chimeric antigen receptor T-cell therapy as treatment of patients with solid tumors and how this is evolving compared to CAR T cells in hematologic malignancies.

Prashant Kapoor, MD

Latest:

Dr. Kapoor on Advice for Oncologists Treating Patients With Myeloma

Prashant Kapoor, MD, hematologic oncologist, Mayo Clinic, shares advice for community oncologists who are treating patients with multiple myeloma.

Praveen Ramakrishnan, MD

Latest:

Dr. Ramakrishnan on Negative Results of the BELINDA Trial in Non-Hodgkin Lymphoma

Praveen Ramakrishnan, MD, discusses the negative results from the phase 3 BELINDA trial and its effect on the use of CAR T-cell products in aggressive B-cell non-Hodgkin lymphoma.

Preet M. Chaudhary, MD, PhD

Latest:

Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.

Preetesh Jain, MD, PhD

Latest:

Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL

Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.

Premal H. Thaker, MD, MS

Premal H. Thaker, MD,MS is the David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology; Director, Gynecological Oncology Clinical Research; Interim Chief, Division of Gynecologic Oncology.

Latest:

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.